Literature DB >> 26224307

Predicting and preventing the development of rheumatoid arthritis.

Karim Raza1, Lars Klareskog2, V Michael Holers3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26224307      PMCID： PMC5854029          DOI： 10.1093/rheumatology/kev261

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  10 in total

1.  Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins.

Authors:  Aase Haj Hensvold; Patrik K E Magnusson; Vijay Joshua; Monika Hansson; Lena Israelsson; Ricardo Ferreira; Per-Johan Jakobsson; Rikard Holmdahl; Lennart Hammarström; Vivianne Malmström; Johan Askling; Lars Klareskog; Anca Irinel Catrina
Journal:  Ann Rheum Dis       Date:  2013-11-25       Impact factor: 19.103

Review 2.  Gene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis.

Authors:  Anca I Catrina; Kevin D Deane; Jose U Scher
Journal:  Rheumatology (Oxford)       Date:  2014-12-23       Impact factor: 7.580

3.  Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity?

Authors:  M Kristen Demoruelle; Michael H Weisman; Philip L Simonian; David A Lynch; Peter B Sachs; Isabel F Pedraza; Annie R Harrington; Jason R Kolfenbach; Christopher C Striebich; Quyen N Pham; Colin D Strickland; Brian D Petersen; Mark C Parish; Lezlie A Derber; Jill M Norris; V Michael Holers; Kevin D Deane
Journal:  Arthritis Rheum       Date:  2011-12-19

4.  The role of the shared epitope in arthralgia with anti-cyclic citrullinated peptide antibodies (anti-CCP), and its effect on anti-CCP levels.

Authors:  W H Bos; J Ursum; N de Vries; G M Bartelds; G J Wolbink; M T Nurmohamed; I E van der Horst-Bruinsma; R J van de Stadt; J B A Crusius; P P Tak; B A C Dijkmans; D van Schaardenburg
Journal:  Ann Rheum Dis       Date:  2008-04-03       Impact factor: 19.103

Review 5.  Strategies to predict rheumatoid arthritis development in at-risk populations.

Authors:  Elizabeth W Karlson; Dirkjan van Schaardenburg; Annette H van der Helm-van Mil
Journal:  Rheumatology (Oxford)       Date:  2014-08-04       Impact factor: 7.580

6.  Development of autoantibodies before the clinical onset of systemic lupus erythematosus.

Authors:  Melissa R Arbuckle; Micah T McClain; Mark V Rubertone; R Hal Scofield; Gregory J Dennis; Judith A James; John B Harley
Journal:  N Engl J Med       Date:  2003-10-16       Impact factor: 91.245

7.  Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials.

Authors:  Karim Raza; Tajvur P Saber; Tore K Kvien; Paul P Tak; Danielle M Gerlag
Journal:  Ann Rheum Dis       Date:  2012-08-31       Impact factor: 19.103

Review 8.  The genetics of rheumatoid arthritis: risk and protection in different stages of the evolution of RA.

Authors:  Annie Yarwood; Tom W J Huizinga; Jane Worthington
Journal:  Rheumatology (Oxford)       Date:  2014-09-18       Impact factor: 7.580

9.  EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis.

Authors:  Danielle M Gerlag; Karim Raza; Lisa G M van Baarsen; Elisabeth Brouwer; Christopher D Buckley; Gerd R Burmester; Cem Gabay; Anca I Catrina; Andrew P Cope; François Cornelis; Solbritt Rantapää Dahlqvist; Paul Emery; Stephen Eyre; Axel Finckh; Steffen Gay; Johanna M Hazes; Annette van der Helm-van Mil; Tom W J Huizinga; Lars Klareskog; Tore K Kvien; Cathryn Lewis; Klaus P Machold; Johan Rönnelid; Dirkjan van Schaardenburg; Georg Schett; Josef S Smolen; Sue Thomas; Jane Worthington; Paul P Tak
Journal:  Ann Rheum Dis       Date:  2012-03-02       Impact factor: 19.103

Review 10.  Towards prevention of autoantibody-positive rheumatoid arthritis: from lifestyle modification to preventive treatment.

Authors:  Danielle M Gerlag; Jill M Norris; Paul P Tak
Journal:  Rheumatology (Oxford)       Date:  2015-09-15       Impact factor: 7.580
  10 in total
  4 in total

Review 1.  Perspectives of at-Risk Individuals on Preventive Intervention for Rheumatoid Arthritis: A Mini Review.

Authors:  Marie Falahee; Karim Raza
Journal:  Front Immunol       Date:  2022-04-29       Impact factor: 8.786

2.  Comparison of the diagnostic potential of three anti-citrullinated protein antibodies as adjuncts to rheumatoid factor and CCP in a cohort of South African rheumatoid arthritis patients.

Authors:  Pieter W A Meyer; Mahmood T M Ally; Bridget Hodkinson; Ronald Anderson; Mohammed Tikly
Journal:  Rheumatol Int       Date:  2018-04-30       Impact factor: 2.631

3.  High miR-451 expression in peripheral blood mononuclear cells from subjects at risk of developing rheumatoid arthritis.

Authors:  Klára Prajzlerová; Olga Kryštůfková; Petra Hánová; Veronika Horváthová; Monika Gregová; Karel Pavelka; Jiří Vencovský; Ladislav Šenolt; Mária Filková
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379

4.  Type 2 diabetes mellitus, glycaemic control, associated therapies and risk of rheumatoid arthritis: a retrospective cohort study.

Authors:  Dawit T Zemedikun; Krishna Gokhale; Joht Singh Chandan; Jennifer Cooper; Janet M Lord; Andrew Filer; Marie Falahee; Krishnarajah Nirantharakumar; Karim Raza
Journal:  Rheumatology (Oxford)       Date:  2021-12-01       Impact factor: 7.580
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.